A Face-Off With Gilead? Incyte Execs Are Upbeat About Jakafi
This article was originally published in The Pink Sheet Daily
Gilead’s looming entrance into the increasingly competitive myelofibrosis market doesn’t phase Incyte executives, who remain upbeat about their first-in-class MF drug Jakafi. More than a year after its launch in November 2011, they point to new data demonstrating the drug’s overall survival benefits and greater clarity around optimal titration.